13 results about "Major depressive disorder" patented technology

The present disclosure relates to a method of treating depression and / or reducing the risk of suicide comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride (or a molar equivalent of bupropion in another form) and about 40 mg to about 50 mg of dextromethorphan hydrobromide (or a molar equivalent of dextromethorphan in another form). The combination can be administered twice a day to a person with major depressive disorder and a score of 3 or higher on the suicide ideation item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI).

This invention relates to the field of microbial pharmaceutical technology, specifically disclosing the application of *Blautia Obeum* in the preparation of drugs for the prevention and treatment of depression, representing a novel use of probiotics for antidepressant purposes. This invention is the first to apply *Blautia Obeum* to the prevention and treatment of depression. This strain can be prepared in various forms, including live bacterial preparations, inactivated bacterial cells, bacterial lysates, metabolites, or bacterial extracts, combined with pharmaceutically acceptable excipients to formulate various oral microecological preparations, including conventional dosage forms such as tablets, capsules, enteric-coated preparations, and oral liquids. The drugs can effectively improve core clinical symptoms of depression, such as low mood, loss of interest, sleep disorders, anxiety, and irritability, by regulating intestinal flora homeostasis, repairing intestinal barrier function, and modulating the brain-gut axis signaling pathway. It is suitable for the prevention and treatment of various types of depression, including major depressive disorder, postpartum depression, geriatric depression, and chronic stress-induced depression. The strain used in this invention is safe and highly compatible, and the preparation is convenient to administer, providing a novel microecological intervention scheme for the clinical prevention and treatment of depression, overcoming some limitations of existing antidepressant methods, and possessing good prospects for pharmaceutical development.

The present disclosure relates to a method of treating depression and / or reducing the risk of suicide comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride (or a molar equivalent of bupropion in another form) and about 40 mg to about 50 mg of dextromethorphan hydrobromide (or a molar equivalent of dextromethorphan in another form). The combination can be administered twice a day to a person with major depressive disorder and a score of 3 or higher on the suicide ideation item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI).

The present disclosure relates to methods of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, by administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof. The disclosure also relates to methods of treating postpartum depression (PPD) with elevated anxiety in a subject in need thereof, by administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof.

Disclosed is the use of spermidine as a biomarker for monitoring the treatment response in major depressive disorder (MDD). Also disclosed are methods for assessing a response to an MDD treatment in a patient having MDD, antidepressants for use in treatment of MDD and methods of treating MDD.

The application discloses a method and system for assisting in evaluating major depressive disorder based on a phenotype fusion sparse graph, and the method comprises the following steps: acquiring multi-modal data of multiple subjects; pre-processing brain function image data to construct a sparse brain function connection graph of each subject; extracting subgraph embedding features from the sparse brain function connection graph of each subject based on a learnable attention mechanism and a TopK pooling method optimized through information fidelity constraints; fusing the subgraph embedding features and individual feature data to construct a subject relationship graph; inputting the subject relationship graph into a graph neural network classifier containing a dynamic residual weight block, training the classifier under the supervision of a doctor's diagnosis label, and obtaining a classification model; and inputting brain function image data and individual feature data of a subject to be evaluated into the trained classification model to obtain an auxiliary evaluation result of major depressive disorder. The application can realize efficient and traceable MDD auxiliary evaluation.

Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

This disclosure relates to dosage forms comprising: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of dextromethorphan; and 2) about 25-35 mg, about 29-31 mg, about 30 mg, about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan. In some embodiments, a dosage form as described herein is free of a Compound I and Compound II. In some embodiments, a dosage form may contain 0.5 ng to 750 ng of Compound I, 0.5 ng to 750 ng of Compound II, or a combination thereof. These dosage forms may be used to treat various neurological and psychiatric conditions, including major depressive disorder, agitation associated with Alzheimer's disease, and nicotine addiction.

Disclosed herein are methods of treating attention deficit / hyperactivity disorder (ADHD), major depressive disorder (MDD), binge eating disorder (BED), or shift work disorder (SWD) in a human, such as an adult, by administering safinamide to a human having ADHD, MDD, BED, or SWD. Safinamide can be administered in the morning, such as within one hour of waking. In some embodiments, safinamide is administered more than 9 hours before the expected bedtime.

The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders such as suicidality, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.

The present invention relates to the use of a combination of two or more of a D2 agonist, an adenosine A2A receptor antagonist, a histamine H3 antagonist or inverse agonist, a mGluR5 receptor antagonist, or a nicotinic α4-β2 and / or α7 receptor agonist to increase D2 dopaminergic molecular signaling in the striatum for the treatment of psychiatric or neurological disorders in which anhedonia or motivation-related dysfunction exists (such as major depressive disorder, bipolar I or II disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative symptoms) and Parkinson's disease (e.g. non-motor features such as depression and apathy)).